Renejix CDMO Partner for Small Molecule Oral Dosage Forms Renejix CDMO Partner for Small Molecule Oral Dosage Forms

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Ionetix","sponsor":"Point Biopharma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"POINT Biopharma and IONETIX Announce Ac-225 Supply Agreement","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Ionetix","sponsor":"Precision Molecular","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"IONETIX and PRECISION MOLECULAR Inc. Announce Supply Agreement for Astatine-211","therapeuticArea":"Oncology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2022","url1":"","url2":"","graph1":"Oncology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Ionetix","sponsor":"Convergent Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Convergent Therapeutics and IONETIX Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Ionetix

    Menu

    Ionetix

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Ionetix

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Convergent Therapeutics and IONETIX Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)

              Details:

              The agreement will support Convergent's pipeline of next-generation radiotherapies including its lead asset, CONV01-α (225Ac−Rosopatamab), a prostate-specific membrane antigen (PSMA)-targeted monoclonal antibody linked to Ac-225.

              Lead Product(s): 225Ac−rosopatamab,177Lu-PSMA-I&T,68Ga-PSMA-11

              Therapeutic Area: Oncology Product Name: CONV01-alpha

              Highest Development Status: Phase I/ Phase II Product Type: Large molecule

              Recipient: Convergent Therapeutics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement May 25, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Ionetix

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              IONETIX and PRECISION MOLECULAR Inc. Announce Supply Agreement for Astatine-211

              Details:

              Astatine-211 is a high-energy alpha-emitting radioisotope that can have a very powerful therapeutic effect when combined with the right targeting molecule. PMI is developing an astatine-211 labeled inhibitor of prostate-specific membrane antigen (PSMA) known as PMI21.

              Lead Product(s): PMI21

              Therapeutic Area: Oncology Product Name: PMI21

              Highest Development Status: IND Enabling Product Type: Small molecule

              Partner/Sponsor/Collaborator: Precision Molecular

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement January 26, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Ionetix

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              POINT Biopharma and IONETIX Announce Ac-225 Supply Agreement

              Details:

              PDS Biotechnology licenses National Cancer Institute for intellectual property related to tumor-associated active T-cell receptor gamma. The administration of PDS0102, Versamune-TARP tumor antigen combination, led to induction of large numbers of tumor targeted killer T-cells.

              Lead Product(s): PNT2001,Actinium-225

              Therapeutic Area: Oncology Product Name: PNT2001

              Highest Development Status: Preclinical Product Type: Large molecule

              Recipient: Point Biopharma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement November 09, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY